SALT
LAKE CITY, Oct. 31, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today the list of events it has chosen to exhibit at or
attend during November, 2023, which strategically align with its
mission of increasing accessibility of affordable gold-standard PCR
diagnostics around the world.
At each event, the Company will discuss its upcoming at-home and
point-of-care Co-Dx™ PCR platform technology*, which has been
designed to bring PCR diagnostics to the point-of-care as the world
adjusts to a post-pandemic diagnostics landscape.
- Utah Life Sciences Summit in Salt
Lake City; Nov. 9, 2023: This
event will feature leading experts in the life sciences industry
gathered from around the country. "A study by Advamed ranked
Utah as #8 in the country for
production of medical devices and #9 for total employees in the
medical device space." Co-Dx CSO Dr. Mark
Poritz will be participating in a "Developments in
Diagnostics" panel, and the Company can be visited at its
booth.
- AMP in Salt Lake City;
Nov. 14-18, 2023: The Association for
Molecular Pathology (AMP) is a leading organization in the field of
molecular diagnostics. Its annual meeting gathers leading molecular
professionals to explore "how cutting-edge technology and
developments in molecular testing continue to have a major and
direct impact on patient care." Attendees are invited to Booth
#1501 to learn more about the Company. Co-Dx CEO Dwight Egan will also be giving an innovation
spotlight presentation on Stage #1 at 9:30-10:30 AM MT on November 17, 2023.
- MEDICA held in Düsseldorf, Germany; Nov. 13-16,
2023: "With more than 4,500 exhibitors from 66 countries and
more than 81,000 visitors from all over the world, MEDICA is one of
the largest medical B2B trade fairs in the world." The Company can
be found at Booth #3 D15-1, and will also be giving a presentation
on its upcoming Co-Dx PCR platform in the "Diagnostics and Health
Monitoring—Pushing the frontiers of diagnostics" session at
11:05 AM CET on Thursday, November
16.
- World Conference on Lung Health in Paris, France; Nov.
15-18, 2023: Every year for 53 years, The Union World
Conference on Lung Health has come together to present the latest
scientific research in all aspects of lung health, with this year's
theme being "Transforming Evidence into Practice." Co-Dx
representatives will be attending the event to visit with current
and potential international supporters of the Company's mission and
vision, and the upcoming platform will be featured in a
presentation.
- NIH Research and Innovation Translation Partnerships in
Point-of-Care Technologies Conference and Technology Showcase at
the NIH Main Campus in Bethesda,
Maryland; Nov. 28-29, 2023:
The conference brings together innovators who are "accelerating
point-of-care and home-based diagnostic technology innovation,
validation, and commercialization." The Company has been invited to
demonstrate its technology platform and the Co-Dx PCR Pro™ on
November 29 at the exhibition.
*The Co-Dx PCR at-home and point-of-care platform (including
the PCR Home™, PCR Pro™, mobile app, and all associated test kits)
is subject to review by the FDA and/or other regulatory bodies and
is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding our belief that our
new platform will help support the Company's worldwide efforts to
help prevent the spread of infectious diseases and our belief that
our new platform has the potential to dramatically improve access
to diagnostics and reduce healthcare costs. Actual results may
differ materially from those contemplated or anticipated by such
forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 16, 2023, and in our other filings with the
SEC. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-shares-list-of-upcoming-industry-conferences-and-events-for-november-2023-301972458.html
SOURCE Co-Diagnostics